Relevant BNF section: 6.7.1
In 1976 we heralded the introduction of bromocriptine (Parlodel - Sandoz) as "an important advance" for the treatment of patients with hyperprolactinaemia.1 Now two new drugs are available for treating hyperprolactinaemia; cabergoline (▼Dostinex - Pharmacia) which the manufacturer claims offers "a significant advance in prolactin control" and quinagolide (▼Norprolac - Sandoz) for which the claim is of a "significant advance in the therapy of hyperprolactinaemia". Do these newer products hold real advantages?
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.